Literature DB >> 16942989

Viable counts, characteristic evaluation for commercial lactic acid bacteria products.

Wen-Hsin Lin1, Chin-Fa Hwang, Li-Wei Chen, Hau-Yang Tsen.   

Abstract

Eight commercial lactic acid bacteria (LAB) products were assayed for their LAB cell counts, acid and bile tolerance, and adherence to human intestinal epithelium. Results showed that the viable cell densities in liquid products, such as fermented milk samples, were higher than those in the solid products. In two solid products, viable LAB counts were not found indicating the incorrect labeling on the package. With a simulated human gastrointestinal digestion system, LAB strains from different commercial products were found to have different acid and bile tolerance. Twenty five LAB isolates from five commercial products were assayed for their antagonistic activities against bacterial pathogens, such as Staphylococcus aureus, Escherichia coli including enterotoxigenic strain, and Salmonella typhimurium. The spent culture supernatant (SCS) from some LAB isolates significantly inhibited the growth of these indicator bacteria. Among these 25 isolates, only five from one commercial product exhibited weak adherence to the human intestinal epithelial cells (Int-407). The rest showed no adherence at all. In conclusion, only few commercial LAB products meet the basic requirements for probiotic functions.

Entities:  

Mesh:

Year:  2006        PMID: 16942989     DOI: 10.1016/j.fm.2005.01.013

Source DB:  PubMed          Journal:  Food Microbiol        ISSN: 0740-0020            Impact factor:   5.516


  33 in total

1.  Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery: a randomized control trial.

Authors:  James Kinross; Oliver Warren; David Silk; Ara Darzi
Journal:  Ann Surg       Date:  2007-06       Impact factor: 12.969

2.  Probiotic Potential of Pediococcus pentosaceus CRAG3: A New Isolate from Fermented Cucumber.

Authors:  Rishikesh Shukla; Arun Goyal
Journal:  Probiotics Antimicrob Proteins       Date:  2014-03       Impact factor: 4.609

3.  Enterococcus mundtii ST4SA and Lactobacillus plantarum 423 alleviated symptoms of Salmonella infection, as determined in Wistar rats challenged with Salmonella enterica serovar Typhimurium.

Authors:  Leon M T Dicks; Kim ten Doeschate
Journal:  Curr Microbiol       Date:  2010-02-02       Impact factor: 2.188

4.  Kimchi bacteriophages of lactic acid bacteria: population, characteristics, and their role in watery kimchi.

Authors:  Won-Jeong Park; Se-Jin Kong; Jong-Hyun Park
Journal:  Food Sci Biotechnol       Date:  2021-07-06       Impact factor: 3.231

5.  Potent antagonistic activity of Egyptian Lactobacillus plantarum against multiresistant and virulent food-associated pathogens.

Authors:  Lamiaa A Al-Madboly; Abeer K Abdullah
Journal:  Front Microbiol       Date:  2015-05-12       Impact factor: 5.640

6.  In vitro selection and characterization of new probiotic candidates from table olive microbiota.

Authors:  Cristian Botta; Tomaz Langerholc; Avrelija Cencič; Luca Cocolin
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

7.  Probiotic properties of Lactobacillus strains isolated from gizzard of local poultry.

Authors:  Tayeb Idoui
Journal:  Iran J Microbiol       Date:  2014-04

8.  The efficacy of three double-microencapsulation methods for preservation of probiotic bacteria.

Authors:  Pawiya Pupa; Prasert Apiwatsiri; Wandee Sirichokchatchawan; Nopadon Pirarat; Nongnuj Muangsin; Asad Ali Shah; Nuvee Prapasarakul
Journal:  Sci Rep       Date:  2021-07-02       Impact factor: 4.379

9.  Probiotic as a novel treatment strategy against liver disease.

Authors:  Abbas Ali Imani Fooladi; Hamideh Mahmoodzadeh Hosseini; Mohammad Reza Nourani; Soghra Khani; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2013-02-25       Impact factor: 0.660

Review 10.  Probiotics and Alcoholic Liver Disease: Treatment and Potential Mechanisms.

Authors:  Fengyuan Li; Kangmin Duan; Cuiling Wang; Craig McClain; Wenke Feng
Journal:  Gastroenterol Res Pract       Date:  2015-12-29       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.